Fig 1: Immunohistochemistry staining for Braf mutant (BRAFV600E) protein. (A) Well-differentiated adenocarcinoma showing negative staining of BRAF (×200). (B) Well-differentiated adenocarcinoma showing weak cytoplasmic staining (×400). (C) Moderately differentiated adenocarcinoma showing moderate cytoplasmic staining (×200). (D) Moderately differentiated adenocarcinoma showing strong cytoplasmic staining (×400). (E) Poorly differentiated adenocarcinoma showing cytoplasmic staining (×200). (F) Poorly differentiated adenocarcinoma showing nuclear staining (×200). (G) Signet ring nuclei showing scattered few positively stained nuclei (200). (H) Mucinous adenocarcinoma showing negative staining of the BRAF mutation (×100).
Fig 2: Sporadic recurrent MPTC sized 8 mm (pT1aN0M0 at the first operation) removed from a 22-year-old male patient: (A–D) primary tumor, (E–H) the RAI-R recurrent metastasis. (A) Nonencapsulated primary tumor with follicular-papillary (conventional) growth pattern with extrathyroidal extension to the connective tissue, H&E, 15X magnification. (B) Fragment of the primary tumor with papillary structures featuring tall cell areas and oncocytic changes, H&E, 400X magnification. (C) Primary tumor: positive IHC reaction with the anti-BRAF (mutated V600E) antibody, 400X magnification. (D) Primary tumor: IHC reaction with Ki67 (Clone MIB-1) antibody (Ki67 LI 3.1%), 400X magnification. (E) RAI-R recurrent metastasis with cystic changes removed 1.3 years after the first surgery, H&E, 15X magnification. (F) Fragment of the RAI-R recurrent metastasis with solid structure and oncocytic changes, H&E, 400X magnification. (G) fragment of the RAI-R recurrent metastasis: positive IHC reaction with anti-BRAF (mutated V600E) antibody, 400X magnification. (H) RAI-R recurrent metastasis: IHC reaction with Ki67 (Clone MIB-1) antibody (Ki67 LI 3.3%), 400X magnification.
Fig 3: Baseline, radiation exposure, and clinicopathological profiles of 428 radiogenic PTCs in the study arranged by IHC BRAF status.
Fig 4: The BRAFV600E-positive radiogenic PTC: (A–C) primary tumor, (D–F) primary lymph node metastasis, and (G–I) an RAI-R recurrent metastasis removed 2.8 years after the first surgery, all images are at 200X magnification. (A) Primary tumor with trabecular-papillary growth pattern, tall cell variant, H&E; (B) positive IHC reaction with anti-BRAF (mutated V600E) antibody; (C) IHC reaction with Ki67 (Clone MIB-1) antibody (Ki67 LI 5.4%). (D) Primary oncocytic cell metastasis with solid-trabecular dominant growth pattern, H&E; (E) positive IHC reaction with anti-BRAF antibody; (F) IHC reaction with Ki67 antibody (Ki67 LI 3.3%). (G) RAI-R recurrent oncocytic cell metastasis with solid-trabecular growth pattern, H&E; (H) positive IHC reaction with anti-BRAF antibody; (I) IHC reaction with Ki67 antibody (Ki67 LI 3.3%).
Fig 5: Immunohistochemical staining for BRAFV600E and Ki67. (a–c) the BRAFV600E-positive, and (d–f) the BRAFV600E-negative radiogenic PTCs. (a)—papillary dominant growth pattern, hematoxylin-eosin, ×200; (b)—positive IHC reaction with the VE1 anti-BRAF (mutated V600E) antibody, ×200; (c)—IHC reaction with Ki67 (Clone MIB-1) antibody (Ki67 LI 8.7%), ×200; (d)—solid dominant growth pattern, hematoxylin-eosin, ×200; (e)—negative IHC reaction with the VE1 anti-BRAF (mutated V600E) antibody,×200; (f)—IHC reaction with Ki67 (Clone MIB-1) antibody (Ki67 LI 2.4%), ×200.
Supplier Page from Abcam for Anti-BRAF (mutated V600E) antibody [VE1]